Charles Matthew Mallinson, P.D, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3118 N River Blvd, Sugar Creek, MO 64050 Phone: 816-590-7979 |
News Archive
Against the background of the COVID-19 pandemic, the impact of SARS-CoV-2 infection in pregnancy has been a subject of much controversy. In order to help answer the question as to whether this infection causes significant harm in pregnancy, a new study, released as a medRxiv* preprint, reports on the disease outcomes of this infection in pregnant women.
Take a look in your pantry: the miracle ingredient for fighting obesity may already be there. A simple potato extract may limit weight gain from a diet that is high in fat and refined carbohydrates, according to scientists at McGill University. The results of their recent study were so surprising that the investigators repeated the experiment just to be sure.
BioMimetic Therapeutics, today announced highlights from its analyst and investor meeting which was held on Thursday, February 17 in San Diego, CA in conjunction with the American Academy of Orthopedic Surgery Annual Meeting.
Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a study at the American Association for Cancer Research's 102nd Annual Meeting 2011 that identifies a key enzyme in non-small cell lung cancers that could potentially make standard chemotherapy more effective against this highly deadly disease.
Patterson Companies, Inc. today reported consolidated sales of $789,579,000 for the first quarter of fiscal 2010 ended July 25, an increase of 6% from $743,859,000 in the year-earlier quarter. The strong performance of technology offerings in the dental equipment business, as well as higher sales of veterinary supplies, helped offset the impact of the weak economy on other portions of Patterson's business. Acquisitions, net of negative foreign currency adjustments, accounted for the majority of the first quarter sales growth. Net income was $45,057,000 or $0.38 per diluted share, compared to $45,964,000 or $0.39 per diluted share in the first quarter of 2009.
› Verified 9 days ago